Headquartered in Galway, Ireland, Neurent Medical develops innovative non-surgical treatments for chronic inflammatory sino-nasal diseases. By targeting and safely disrupting the hyperactive autonomic nerves that drive underlying inflammation, their revolutionary treatment provides effective relief to patients. Neurent has its US office in Boston, MA.

This latest funding from the CEGCF III will be used to invest in sales & marketing, product development and to support further US expansion.

Approximately one in four Americans suffer from chronic rhinitis, a common condition that results in persistent symptoms including congestion, rhinorrhea, sneezing and nasal itching. Chronic rhinitis significantly decreases quality of life and can have an adverse effect on sleep quality, mood, and daily activities.

The traditional rhinitis patient journey is often full of frustration due to limited treatment options. The NEUROMARK System is a minimally invasive treatment option designed to target the underlying drivers of chronic rhinitis. The NEUROMARK System enables the physician to simultaneously treat multiple nerve branches with a high degree of precision, safety, and patient comfort.

Daniel Mallon, Principal at Claret Capital Partners commented: “Neurent Medical is addressing a critical gap in healthcare, and we are hugely excited to be supporting the team as they continue to fulfil their mission to transform the treatment and standard of care in chronic rhinitis.”

Brian Shields, CEO and Co-Founder at Neurent Medical said: “Neurent Medical welcomes Claret Capital Partners to our investment syndicate. Their success in investing in high growth companies brings valuable experience to the Neurent Medical team and will serve us well on the next phase of our journey.”

Joey Mason, Venture Partner at Claret Capital Partners added: “The company is poised to establish the NEUROMARK System as the standard of care for the millions of people suffering from chronic rhinitis. We are delighted to be joining the strong syndicate of existing investors and to supporting the company’s excellent management team.”

Claret has a long track record of investing in the Medical Device sector – previous investments include Cardiac Dimensions, Endomag, and Spineguard.

Both AIB (Allied Irish Bank), and ISIF (The Ireland Strategic Investment Fund), are Limited Partners in the CEGCF III.